Table 2. Adverse Events During the First... | American Society of Hematology

Table 2.

Adverse Events During the First Administration of Rituximab According to the NCI Adult Toxicity Criteria

Patient Lymphocytes (×10⁹/L)	Group A					Group B
Patient Lymphocytes (×10⁹/L)	No. 1 0.2	No. 2 6.5	No. 3 7.7	No. 4 11.5	No. 5 37.2	No. 6 60.8	No. 7 68.1	No. 8 71.1	No. 9 89.3	No. 10 124.0	No. 11 294.3
Chills	0	0	I	I	0	III	I	0	II	0	II
Fever	0	I	II	I	0	I	II	0	II	I	0
Dyspnea	0	0	0	0	0	I	0	I	0	0	III
Tachycardia	0	0	0	I	0	I	II	0	II	0	II
Nausea	0	0	0	I	0	0	II	II	III	I	III
Vomiting	0	0	0	0	0	0	0	II	I	I	I
Hypokaliemia	0	0	0	0	0	0	I	0	I	0	I
Hypocalcemia	II	0	I	I	0	0	II	II	II	II	I
Increase of liver enzymes	0	I	0	0	0	II	0	I	III	I	I
Elevation of LDH	I	I	I	0	0	III	I	I	III	I	I
Hyperuricemia	0	I	I	0	I	I	I	II	0	II	I
Hypoproteinemia	I	I	I	I	I	I	I	II	II	I	I
Elevation of CRP	I	I	0	I	I	II	0	I	II	I	0
Elevation of d-dimers	0	I	I	0	I	I	0	I	III	0	I
Prolongation of prothrombin time	0	0	I	0	0	0	0	0	II	0	0
Anemia	NE	0	0	I	0	I	I	II	I	I	I
Thrombocytopenia	0	0	0	0	NE	I	III	I	IV	II	II

Patient Lymphocytes (×10⁹/L)	Group A					Group B
Patient Lymphocytes (×10⁹/L)	No. 1 0.2	No. 2 6.5	No. 3 7.7	No. 4 11.5	No. 5 37.2	No. 6 60.8	No. 7 68.1	No. 8 71.1	No. 9 89.3	No. 10 124.0	No. 11 294.3
Chills	0	0	I	I	0	III	I	0	II	0	II
Fever	0	I	II	I	0	I	II	0	II	I	0
Dyspnea	0	0	0	0	0	I	0	I	0	0	III
Tachycardia	0	0	0	I	0	I	II	0	II	0	II
Nausea	0	0	0	I	0	0	II	II	III	I	III
Vomiting	0	0	0	0	0	0	0	II	I	I	I
Hypokaliemia	0	0	0	0	0	0	I	0	I	0	I
Hypocalcemia	II	0	I	I	0	0	II	II	II	II	I
Increase of liver enzymes	0	I	0	0	0	II	0	I	III	I	I
Elevation of LDH	I	I	I	0	0	III	I	I	III	I	I
Hyperuricemia	0	I	I	0	I	I	I	II	0	II	I
Hypoproteinemia	I	I	I	I	I	I	I	II	II	I	I
Elevation of CRP	I	I	0	I	I	II	0	I	II	I	0
Elevation of d-dimers	0	I	I	0	I	I	0	I	III	0	I
Prolongation of prothrombin time	0	0	I	0	0	0	0	0	II	0	0
Anemia	NE	0	0	I	0	I	I	II	I	I	I
Thrombocytopenia	0	0	0	0	NE	I	III	I	IV	II	II

Taken into account are any abnormalities that occurred during 48 hours after onset of the first antibody infusion.

Abbreviation: NE, not evaluable due to autoimmune thrombocytopenia in patient no. 5 and autoimmune haemolysis in patient no. 1.